Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

Core Viewpoint - Instil Bio, Inc. announced the discontinuation of clinical development for AXN-2510 and the termination of its collaboration agreement with ImmuneOnco Biopharmaceuticals [1][2] Group 1: Company Actions - Axion Bio, Inc., a subsidiary of Instil, has decided to stop the clinical development of AXN-2510 [1] - A termination agreement has been reached between Axion and ImmuneOnco, which includes the reversion of all previously licensed rights to ImmuneOnco [2] Group 2: Licensing and Rights - Under the termination agreement, global development and commercial rights outside Greater China have reverted to ImmuneOnco, with Axion retaining a limited license to wind down its clinical activities [2]